Who owns Phathom Pharmaceuticals, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PHAT from SEC Form 13F filings across 161 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 161 institutions disclosed 70.3M shares of Phathom Pharmaceuticals, Inc. worth $509.2M — about 82.8% of shares outstanding; the largest disclosed holder is Frazier Life Sciences Management, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
161
13F holders
$509.2M
value, 2026 filers
82.8%
of shares outstanding (70.3M sh)
28
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of PHAT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 12.5M | $91.0M | 2.3% | 14.7% | 0.0% |
| 2 | Medicxi Ventures Management (Jersey) Ltd | 7.5M | $54.5M | 43.0% | 8.8% | 0.0% |
| 3 | BlackRock, Inc. | 5.2M | $38.3M | 0.0% | 6.2% | +15.9% |
| 4 | Carlyle Group Inc. | 3.5M | $25.5M | 0.3% | 4.1% | 0.0% |
| 5 | WASATCH ADVISORS LP | 2.9M | $21.5M | 0.2% | 3.5% | +125.1% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2.7M | $20.0M | 0.0% | 3.2% | +2.9% |
| 7 | FRANKLIN TEMPLETON INC | 2.4M | $13.7M | 0.0% | 2.8% | +22.1% |
| 8 | MILLENNIUM MANAGEMENT LLC | 2.4M | $17.5M | 0.0% | 2.8% | -28.9% |
| 9 | GW&K Investment Management, LLC | 2.1M | $15.5M | 0.1% | 2.5% | -1.8% |
| 10 | 683 Capital Management, LLC | 2.0M | $14.6M | 0.6% | 2.4% | +8.1% |
| 11 | STATE STREET CORP | 2.0M | $14.6M | 0.0% | 2.4% | +25.9% |
| 12 | NEA Management Company, LLC | 2.0M | $14.3M | 1.0% | 2.3% | 0.0% |
| 13 | Catalys Pacific, LLC | 1.9M | $13.7M | 6.6% | 2.2% | +26.0% |
| 14 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.8M | $13.4M | 0.0% | 2.2% | +25.5% |
| 15 | Point72 Asset Management, L.P. | 1.5M | $11.0M | 0.0% | 1.8% | +46.9% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $9.7M | 0.0% | 1.6% | +1.4% |
| 17 | Propel Bio Management, LLC | 1.1M | $8.1M | 4.3% | 1.3% | +5.3% |
| 18 | AMERIPRISE FINANCIAL INC | 967,895 | $7.1M | 0.0% | 1.1% | +229.2% |
| 19 | GOLDMAN SACHS GROUP INC | 894,675 | $6.5M | 0.0% | 1.1% | -49.7% |
| 20 | Trexquant Investment LP | 855,542 | $6.2M | 0.0% | 1% | +392.0% |
| 21 | Ensign Peak Advisors, Inc | 813,983 | $5.9M | 0.0% | 1% | -22.6% |
| 22 | HSBC HOLDINGS PLC | 812,913 | $5.9M | 0.0% | 1% | +14.5% |
| 23 | VANGUARD PORTFOLIO MANAGEMENT LLC | 679,320 | $5.0M | 0.0% | 0.8% | -14.7% |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 490,308 | $3.6M | 0.0% | 0.6% | +17.0% |
| 25 | NORTHERN TRUST CORP | 467,802 | $3.4M | 0.0% | 0.6% | +2.1% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.